MSCs are multipotent stem cells that can differentiate into many cell types, the potential clinical indications for MSCs becomes endless. MSCs have been explored in treating heart failure, myocardial infarction (heart attack), osteoarthritis, stroke and spinal cord injury around the world and the results are promising. In addition, the results of thousands of patients who have received MSCs so far had shown MSCs are safe and feasible to be transplanted into patients without any short or long-term side effects up to 10 years.
MSCs is also immunopriviledged and immunosuppressive with strong anti-inflammatory properties that allow it to be used against autoimmune diseases such as Graft Versus Host Disease (GVHD), Crohn's disease, rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).
Cytopeutics is one of the leading and responsible pioneers in stem cell research and treatment. We have published and presented MSCs clinical research findings in international journals and research meetings.
After more than a decade of evidence-based research and development, combining the expertise of scientists around the world, Cytopeutics is now ready to offer its capabilities to help people with diseases that were previously deemed incurable.
Research on MSCs is expanding exponentially. Researchers around the world, including Cytopeutics have proven that MSCs not only can differentiate into tissues of mesodermal origin such adipocytes, chondrocytes, osteocytes, cardiomyocytes, but also can trans-differentiate into tissues of ectodermal origin such as neurons and epithelial cells, and endodermal origin such as insulin-producing islet cells and hepatocytes in vitro and in vivo.
In addition, Cytopeutics is one of the few groups that have successfully induced MSCs into mesangial cells and nerve cells apart from heart cells, cartilage cells and skin tissues. We are also actively researching into different Sources of Mesenchymal Stem Cells to treat different kind of diseases like kidney disease and diabetes. Other than that, Cytopeutics also continues exploring the possibility of allogenic MSCs treatment, which is MSCs transplantation from one donor to another individual.
In Malaysia, we currently have concluded our research in heart failures, heart attack, refractory angina, osteoarthritis, peripheral artery disease and foot ulcer, and we will progressively offer clinically-tested pilot programs under observation with utmost professionalism.